Increasing rates of invasive candidiasis caused by non-albicans Candida species have been reported worldwide. Particular concerns have been raised for C. parapsilosis because of reduced in vitro susceptibility to echinocandins. We identified 212 patients with invasive candidiasis due to non-albicans Candida species (>/=5 cases per species) in 5 clinical trials of caspofungin monotherapy from the pharmaceutical Sponsor's (Merck and Co., Inc.) database: 71 C. parapsilosis, 65 C. tropicalis, 54 C. glabrata, 10 C. krusei, 9 C. guilliermondii, and 5 C. lusitaniae; 167 cases caused by C. albicans were also identified. Efficacy was assessed at the end of caspofungin therapy. Success (favorable overall response) required favorable clinical and microbiological responses. Mean APACHE II score was 16.5 in the non-albicans group and 15.7 in the C. albicans group. Neutropenia at study entry was more common in the non-albicans group (12%) than in the C. albicans group (5%). Median duration of caspofungin therapy was 14 days in both groups. Success rate was 77% in both groups and at least 70% for each non-albicans species: C. parapsilosis 74%, C. tropicalis 71%, C. glabrata 85%, C. krusei 70%, C. guilliermondii 89%, C. lusitaniae 100%. Time to negative blood culture was similar for the various species. Overall mortality was 26% in the non-albicans group and 29% in the C. albicans group. Drug-related serious adverse events and discontinuations due to caspofungin toxicity were uncommon. Although sample sizes were limited, caspofungin demonstrated a favorable efficacy and safety profile in the treatment of invasive candidiasis caused by the following non-albicans Candida species: C. parapsilosis, C. tropicalis, C. glabrata, C. krusei, C. guilliermondii, and C. lusitaniae. PMID: 20231388 [PubMed -as supplied by publisher] 
